NAUT - Nautilus Biotechnology Inc


2.93
-0.090   -3.072%

Share volume: 250,961
Last Updated: 05-12-2026
Measuring And Control Equipment/Lab Analytical Instruments: -0.07%

PREVIOUS CLOSE
CHG
CHG%

$3.02
-0.09
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
37%
Profitability 35%
Dept financing 21%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
9.33%
1 Month
-1.35%
3 Months
33.79%
6 Months
55.03%
1 Year
216.07%
2 Year
7.33%
Key data
Stock price
$2.93
P/E Ratio 
0.00
DAY RANGE
$2.87 - $3.02
EPS 
-$0.51
52 WEEK RANGE
$0.62 - $4.31
52 WEEK CHANGE
$232.35
MARKET CAP 
491.070 M
YIELD 
N/A
SHARES OUTSTANDING 
127.079 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$381,642
AVERAGE 30 VOLUME 
$319,528
Company detail
CEO: Sujal M. Patel
Region: US
Website: nautilus.bio
Employees: 130
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Measuring And Control Equipment/Lab Analytical Instruments
Sector: Manufacturing

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.

Recent news